Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9549-9553

  Wu, Ping ^a   Kudrolli, Tarana A ^a   Chowdhury, Wasim H ^a   Liu, Minzhi M ^a   Rodriguez, Ronald ^a   Lupold, Shawn E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE LIBRARY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SAUPW 1 PEPTIDE; SYNTHETIC PEPTIDE; TRYPTOPHYLGLUTAMINYLPROLYLASPARTYLTHREONYLALANYLHISTIDYLHISTIDYLTRYPTOPHYLALANYLTHREONYLLEUCINE; UNCLASSIFIED DRUG; VIRUS FIBER PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOPANNING; CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; GENE CASSETTE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; TARGET CELL; TUMOR MODEL; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, SURFACE; BASE SEQUENCE; CAPSID PROTEINS; CELL LINE, TUMOR; CLONING, MOLECULAR; GENETIC VECTORS; GLUTAMATE CARBOXYPEPTIDASE II; HEK293 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDE LIBRARY; PROSTATIC NEOPLASMS; PROTEIN BINDING; TRANSPLANTATION, HETEROLOGOUS;

EID: 78649927659     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1760     Document Type: Article

References (20)

1. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007;8:573-87. (Pubitemid 47077278)
2. Barry MA, Hofherr SE, Chen CY, Senac JS, Hillestad ML, Shashkova EV. Systemic delivery of therapeutic viruses. Curr Opin Mol Ther 2009;11:411-20.
3. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63. (Pubitemid 27283756)
4. Lupold SE, Rodriguez R. Adenoviral vectors for prostate cancer gene therapy. Cancer Ther 2005;3:267-84.
5. Shashkova EV, May SM, Doronin K, Barry MA. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther 2009;17:2121-30.
6. Ghosh D, Barry MA. Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J Virol 2005;79:13667-72. (Pubitemid 41508178)
7. Lupold SE, Kudrolli TA, Chowdhury WH, Wu P, Rodriguez R. A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Res 2007;35:e138. (Pubitemid 350201828)
8. Miura Y, Yoshida K, Nishimoto T, Hatanaka K, Ohnami S, Asaka M, et al. Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob. Gene Ther 2007;14:1448-60. (Pubitemid 47500648)
9. Elgamal AA, Holmes EH, Su SL, Tino WT, Simmons SJ, Peterson M, et al. Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 2000;18:10-6. (Pubitemid 30036115)
10. Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008;51:7933-43.
11. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006;66:9171-7. (Pubitemid 44521137)
12. Rege K, Patel SJ, Megeed Z, Yarmush ML. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 2007;67:6368-75. (Pubitemid 47037520)
13. Hoti N, Chowdhury W, Mustafa S, Ribas J, Castanares M, Johnson T, et al. Armoring CRAds with p21/Waf-1 shRNAs - the next generation of oncolytic adenoviruses. Cancer Gene Ther 2010;17:1-13.
14. Peng HH, Wu S, Davis JJ, Wang L, Roth JA, Marini FC 3rd, et al. A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. Anal Biochem 2006;354:140-7. (Pubitemid 43816401)
15. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999;286:1568-71.
16. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008;132:397-409.
17. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 2008;105:5483-8. (Pubitemid 351753889)
18. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P, et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 2008;16:1474-80.
19. Di Paolo NC, van Rooijen N, Shayakhmetov DM. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther 2009;17:675-84.
20. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 2006;87:2487-95.